Osteoporosis Treatment with Denosumab and Bisphosphonates

Comparative Efficacy

The American College of Physicians recommends bisphosphonates (alendronate, risedronate, zoledronic acid) as first-line pharmacologic treatment for osteoporosis due to their established efficacy, safety profile, and lower cost 1, 2
Bisphosphonates are associated with a lower cost compared to denosumab, making them a more cost-effective option for osteoporosis treatment 1

IV bisphosphonates (like zoledronic acid) are typically administered once yearly, which may improve adherence compared to oral bisphosphonates 3

Both bisphosphonates and denosumab are associated with rare but serious adverse events including osteonecrosis of the jaw and atypical femoral fractures 1
The risk of these adverse events increases with longer treatment duration for both medication classes 1
IV bisphosphonates are associated with acute phase reactions including influenza-like symptoms, arthritis, arthralgias, headache, and uveitis 2
Denosumab has been associated with increased risk for infection and rash or eczema 2

For patients with nonmetastatic cancer with osteoporosis or at high fracture risk, bone-modifying agents including oral bisphosphonates, IV bisphosphonates, or denosumab may be offered to reduce fracture risk 4
In cancer patients receiving treatments that cause bone loss, both bisphosphonates and denosumab are effective options 4, 3
For glucocorticoid-induced osteoporosis, oral bisphosphonates are recommended as first-line therapy due to safety, cost, and established efficacy 5, 6, 7, 8
IV bisphosphonates are recommended as second-line therapy for glucocorticoid-induced osteoporosis, followed by teriparatide and then denosumab 6, 7, 8

Determine fracture risk using FRAX or similar tool, and evaluate renal function when considering osteoporosis treatment 4, 5
Consider patient preferences regarding administration route when selecting an osteoporosis treatment 5
For most patients, oral bisphosphonates (alendronate, risedronate) are recommended as first-line treatment 2, 1
If oral administration is problematic, consider IV bisphosphonate (zoledronic acid) as an alternative 2
Denosumab may be considered when patient has failed or is intolerant to bisphosphonate therapy, or when greater BMD increases are desired 1
Cost considerations favor bisphosphonates, especially generic formulations, over denosumab 1